Investing.com - Biocept reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biocept announced earnings per share of $-0.040 on revenue of $17.47M. Analysts polled by Investing.com anticipated EPS of $-0.160 on revenue of $9.14M.
Biocept shares are down 76% from the beginning of the year , still down 80.89% from its 52 week high of $4.40 set on Wednesday, December 1, 2021.
Biocept follows other major Healthcare sector earnings this month
Biocept's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar